279 related articles for article (PubMed ID: 9513693)
21. Role of DNA image cytometry in the follow-up of patients with urinary tract transitional cell carcinoma.
Shabaik AS; Pow-Sang JM; Lockhart J; Nicosia SV
Anal Quant Cytol Histol; 1993 Apr; 15(2):115-23. PubMed ID: 8318126
[TBL] [Abstract][Full Text] [Related]
22. Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations.
Veltri RW; Partin AW; Miller MC
J Cell Biochem Suppl; 2000; Suppl 35():151-7. PubMed ID: 11389545
[TBL] [Abstract][Full Text] [Related]
23. Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria.
Paoluzzi M; Cuttano MG; Mugnaini P; Salsano F; Giannotti P
Arch Ital Urol Androl; 1999 Feb; 71(1):13-8. PubMed ID: 10193018
[TBL] [Abstract][Full Text] [Related]
24. Two-dimensional agnor evaluation as a prognostic variable in urinary bladder carcinoma: a different approach via total agnor area/nucleus area per cell.
Cucer N; Imamoglu N; Tozak H; Demirtas H; Sarac F; Tatlisen A; Oztürk F
Micron; 2007; 38(6):674-9. PubMed ID: 17011198
[TBL] [Abstract][Full Text] [Related]
25. Clinical utility of squamous and transitional nuclear structure alterations induced by Schistosoma haematobium in chronically infected adults with bladder damage verified by ultrasound in Ghana.
Naples J; Isharwal S; Shiff CJ; Bosompem KM; Veltri RW
Anal Quant Cytol Histol; 2009 Jun; 31(3):143-52. PubMed ID: 19634785
[TBL] [Abstract][Full Text] [Related]
26. Split-sample comparison of urothelial cells in ThinPrep and cytospin preparations in urinary cytology: Do we need to adjust The Paris System for Reporting Urinary Cytology criteria?
Richardson CJ; Pambuccian SE; Barkan GA
Cancer Cytopathol; 2020 Feb; 128(2):119-125. PubMed ID: 31774630
[TBL] [Abstract][Full Text] [Related]
27. Validation of the novel indices of nuclear pleomorphism, polarity and spatial distribution in the grading of urothelial carcinoma.
Sabo E; Gibrat M; Sova Y; Stein A; Resnick MB
Anal Quant Cytol Histol; 2003 Feb; 25(1):53-62. PubMed ID: 12630083
[TBL] [Abstract][Full Text] [Related]
28. [Urinary NMP22 as a new marker in patients with transitional cell carcinoma].
Muzzonigro G; Minardi D; Galosi AB; Recchioni A; De Sio G; Polito M
Arch Ital Urol Androl; 1999 Jun; 71(3):171-7. PubMed ID: 10431409
[TBL] [Abstract][Full Text] [Related]
29. Quantitative assessment of bladder cancer by nuclear texture analysis using automated high resolution image cytometry.
Gschwendtner A; Hoffmann-Weltin Y; Mikuz G; Mairinger T
Mod Pathol; 1999 Aug; 12(8):806-13. PubMed ID: 10463483
[TBL] [Abstract][Full Text] [Related]
30. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
[TBL] [Abstract][Full Text] [Related]
31. Further testing of morphometric grading in T(A,1) urothelial carcinomas of the urinary bladder and the additional value of p53 immunoquantitation.
Bol MG; Baak JP; Janssen EA; Breeuwsma NG; de Bruin PC
Anal Quant Cytol Histol; 2002 Apr; 24(2):114-20. PubMed ID: 12026049
[TBL] [Abstract][Full Text] [Related]
32. The cytologic diagnosis of low-grade transitional cell carcinoma.
Hughes JH; Raab SS; Cohen MB
Am J Clin Pathol; 2000 Nov; 114 Suppl():S59-67. PubMed ID: 11996171
[TBL] [Abstract][Full Text] [Related]
33. [A morphometric grading study on the nucleus shape and DNA-content of transitional cell carcinoma of urinary bladder].
Xia TL
Zhonghua Bing Li Xue Za Zhi; 1992 Aug; 21(4):202-5. PubMed ID: 1473202
[TBL] [Abstract][Full Text] [Related]
34. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
35. Value of computer-assisted quantitative nuclear morphometry for differentiation of reactive renal tubular cells from low-grade urothelial carcinoma.
Ohsaki H; Hirakawa E; Kagawa K; Nakamura M; Kiyomoto H; Haba R
Cytopathology; 2010 Oct; 21(5):334-8. PubMed ID: 20105210
[TBL] [Abstract][Full Text] [Related]
36. An objective morphologic parameter to aid in the diagnosis of flat urothelial carcinoma in situ.
Milord RA; Lecksell K; Epstein JI
Hum Pathol; 2001 Sep; 32(9):997-1002. PubMed ID: 11567231
[TBL] [Abstract][Full Text] [Related]
37. Image analysis combined with visual cytology in the early detection of recurrent bladder carcinoma.
Richman AM; Mayne ST; Jekel JF; Albertsen P
Cancer; 1998 May; 82(9):1738-48. PubMed ID: 9576297
[TBL] [Abstract][Full Text] [Related]
38. Standardization, analytical validation, and quality control of intermediate endpoint biomarkers.
Veltri RW; Miller MC; An G
Urology; 2001 Apr; 57(4 Suppl 1):164-70. PubMed ID: 11295618
[TBL] [Abstract][Full Text] [Related]
39. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.
Veltri RW; Partin AW; Epstein JE; Marley GM; Miller CM; Singer DS; Patton KP; Criley SR; Coffey DS
J Cell Biochem Suppl; 1994; 19():249-58. PubMed ID: 7529856
[TBL] [Abstract][Full Text] [Related]
40. Histologic grading of urothelial carcinoma: a reappraisal.
Cheng L; MacLennan GT; Lopez-Beltran A
Hum Pathol; 2012 Dec; 43(12):2097-108. PubMed ID: 22542126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
